ライフサイエンスコーパス: complement-mediated

1 globulin G2a (IgG2a), and neutralization was complement mediated.

2 report that BIVV009 significantly inhibited complement-mediated activation and proliferation of prim

3 Thus, complement-mediated activation of iPLA(2)gamma is mediat

4 specific antibodies inhibited both cell-free complement-mediated and cell-dependent opsonophagocytic

5 ssified to reflect the underlying cause as a complement-mediated and immune complex-mediated disease.

6 ades, which act to protect the parasite from complement-mediated and osmotic lysis.

7 In the CNS, NMO-IgG causes complement-mediated astrocyte damage, inflammatory cell

8 ty against M. catarrhalis through increasing complement-mediated attack, improving phagocytic killing

9 lipid syndrome); or, ultimately, to diagnose complement-mediated atypical hemolytic uremic syndrome (

10 a bacterial immune evasion mechanism against complement-mediated bacterial clearance because FH is a

11 g factor H function, but it can also improve complement-mediated bacterial clearance.

12 1E6 is able to elicit rabbit, but not human, complement-mediated bactericidal activity against mening

13 serum concentrations of fH and its effect on complement-mediated bactericidal activity are unknown.

14 r polysaccharide was also protective against complement-mediated bactericidal activity in human ascit

15 on and has been shown to be resistant to the complement-mediated bactericidal activity of human serum

16 ein (FHbp) expression that were resistant to complement-mediated bactericidal activity of sera from m

17 -fHbp monoclonal antibodies (MAbs) had human complement-mediated bactericidal activity only if the MA

18 Ab502, which did not inhibit fH binding, had complement-mediated bactericidal activity only when test

19 fH, the bacteria became more susceptible to complement-mediated bactericidal activity.

20 ntributes to the resistance of AB307-0294 to complement-mediated bactericidal activity.

21 antibodies (MAbs) tested and elicited serum complement-mediated bactericidal antibody titers in wild

22 f lipid A increases gonococcal resistance to complement-mediated bacteriolysis and cationic antimicro

23 E. coli-challenged baboons, implying reduced complement-mediated bacteriolysis, whereas treated anima

24 H, which enables the meningococcus to resist complement-mediated bacteriolysis.

25 reases the susceptibility of the organism to complement-mediated bacteriolysis.

26 recently reclassified as alternative pathway complement-mediated C3 glomerulopathy (C3G) and immune c

27 is classified as immune complex-mediated or complement-mediated (C3 glomerulopathy).

28 Moreover, antibodies are essential for complement-mediated capture of circulating parasites by

29 he surface of HCV-infected cells may inhibit complement-mediated cell killing.

30 PC lineage cells through A2B5+, O4+, and O1+ complement-mediated cell lysis resulted in a delay in de

31 r H (FH) onto the bacterial surface to evade complement-mediated cell lysis.

32 st abundant human matrix metalloproteases or complement-mediated cell lysis.

33 dent cellular phagocytosis, and Ab-dependent complement-mediated cell lysis.

34 We hypothesize that complement-mediated changes in glial cell function signi

35 rOmpB, and suggest that the ability to evade complement-mediated clearance from the hematogenous circ

36 sident macrophages play an important role in complement-mediated clearance, the receptors coordinatin

37 to prevent Crry-deficient erythrocytes from complement-mediated clearance.

38 and demonstrates a role for this pathway in complement-mediated conditions.

39 ower respiratory tract by protecting against complement-mediated control and clearance.

40 colonic damage via the production of IgM and complement-mediated control of intestinal bacteria.

41 n the other hand, GEF-H1 knockdown augmented complement-mediated cytolysis, suggesting a role for GEF

42 is(y/b) directly, as well as by antibody and complement mediated cytotoxicity (ADCC/CDC), but failed

43 s and in physiologic conditions the superior complement mediated cytotoxicity induced by OFA alone co

44 strated sensitivity of cultured LAM cells to complement mediated cytotoxicity via GD3 antibodies.

45 1 molecules impairs their efficacy to induce complement-mediated cytotoxicity (CDC).

46 body-dependent cellular phagocytosis but not complement-mediated cytotoxicity against CLL cells.

47 We found that several antibodies activate complement-mediated cytotoxicity and that T cells carryi

48 Harnessing complement-mediated cytotoxicity by therapeutic antibodi

49 ARGX-117 prevents complement-mediated cytotoxicity in in vitro models for

50 ha-gal Abs target Plasmodium sporozoites for complement-mediated cytotoxicity in the skin, immediatel

51 endent cell-mediated cytotoxicity (ADCC) and complement-mediated cytotoxicity in vitro, and for anti-

52 llular loop of CD20 and has greater in vitro complement-mediated cytotoxicity than rituximab.

53 Consequently, complement-mediated cytotoxicity was attenuated.

54 mediated ADCC, and a 2.5-fold improvement in complement-mediated cytotoxicity while maintaining restr

55 ntibodies and exert a decoy function against complement-mediated cytotoxicity.

56 rane protein, protects autologous cells from complement-mediated damage by inhibiting complement comp

57 The host is protected from complement-mediated damage by several complement regulat

58 e recognition site on CL-11 thereby reducing complement-mediated damage following ischemic insult.

59 We show that eculizumab protects against complement-mediated damage in murine MFS, providing the

60 treatment, but novel treatments that reduce complement-mediated damage or inhibit the binding of pat

61 o prevent C3b amplification, thus minimising complement-mediated damage to host.

62 Complement-mediated damage to the retinal pigment epithe

63 d by pressure disruption, hypoxic injury, or complement-mediated damage were capable of activating th

64 docytes where acute activation protects from complement-mediated damage, but chronic overactivation l

65 D4 T cells were central in facilitating this complement-mediated damage.

66 mplement proteins that could protect against complement-mediated damage.

67 cent synapses with enhanced vulnerability to complement-mediated degeneration, is highly dependent on

68 has been hypothesized that B. hermsii evades complement-mediated destruction by binding factor H (FH)

69 complement mediated lysis and inhibited the complement-mediated destruction of common gut bacteria.

70 0 is immunologically active and leads to the complement-mediated destruction of Env-expressing cells.

71 with crossmatch-incompatible sera indicated complement-mediated destruction of Fs-positive erythrocy

72 thogen survival is dependent upon evasion of complement-mediated destruction.

73 Thus, aHUS provides an archetypal complement-mediated disease with which to model new ther

74 e are also new opportunities to intervene in Complement-mediated disease.

75 In particular, complement-mediated diseases (or complementopathies) wit

76 ave important implications for understanding complement-mediated diseases because, depending on the c

77 for the description and management of other complement-mediated diseases.

78 way toward new options for the treatment of complement-mediated diseases.

79 ling, and proinflammatory effects in various complement-mediated diseases.

80 apeutics that could have application in many complement-mediated diseases.

81 d precision medicine into a widened field of complement-mediated diseases.

82 hows remarkable clinical benefits in certain complement-mediated diseases.

83 ates for therapeutic development in numerous complement-mediated diseases.

84 ge between different types of thrombotic and complement-mediated disorders.

85 l therapeutic candidate for the treatment of complement-mediated disorders.

86 0 mg/kg) of the anti-C1s antibody BIVV009 in complement-mediated disorders.

87 (triplex association) and (ii) Watson-Crick complement-mediated displacement of the TFO and replacem

88 C proliferation and angiogenesis rather than complement-mediated EC lesions.

89 ts show that SRPX2 protects synapses against complement-mediated elimination in both the thalamus and

90 fection of adult hippocampal neurons induces complement-mediated elimination of presynaptic terminals

91 Properdin deficiency rescued mice from AP complement-mediated embryonic lethality caused by defici

92 d to the hypothesis that SARS-CoV-2 triggers complement-mediated endothelial damage, but the mechanis

93 t microglia regulate neuronal elimination by complement-mediated engulfment of nonapoptotic neurons.

94 tes, which are known to be susceptible to AP complement-mediated extravascular hemolysis.

95 ll as for therapeutic purposes in which only complement-mediated functions are required without the i

96 gamma (iPLA2gamma) is cytoprotective against complement-mediated GEC injury.

97 gamma (iPLA2gamma) is cytoprotective against complement-mediated glomerular epithelial cell injury.

98 athologic features with C3 glomerulopathy, a complement-mediated glomerulopathy that, unlike acute po

99 Here, we report an autosomal dominant complement-mediated GN associated with abnormal increase

100 t only confirm the critical role of C5b-9 in complement-mediated hemolysis and but also highlight the

101 l nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and inhibited both C3 frag

102 afe, well tolerated, and rapidly stopped C1s complement-mediated hemolysis in patients with cold aggl

103 8.4.2 was a potent AP inhibitor that blocked complement-mediated hemolysis in several species.

104 d LA-CFH both performed poorly at preventing complement-mediated hemolysis of ES PspCN, a CFH-binding

105 Complement mediated hemolytic uremic syndrome (aHUS) acc

106 l determinant for pneumococcal resistance to complement-mediated host defense in humans.

107 Complement mediated HUS (aHUS) has a worse prognosis com

108 This may have implications for modulating complement-mediated immune function in the microenvironm

109 ent, provides a powerful approach to inhibit complement-mediated immune responses and tissue injury.

110 A, the main pneumococcal autolysin, inhibits complement-mediated immunity independently of effects on

111 inds to complement component C3b, inhibiting complement-mediated immunity.

112 ight into the molecular processes underlying complement-mediated inflammation and highlight the possi

113 NLRP3 inflammasome activation and complement-mediated inflammation have been implicated in

114 and tangles in AD brain, and thus a role for complement-mediated inflammation in the acceleration or

115 f fH-/- livers (3-24 months) for evidence of complement-mediated inflammation revealed widespread dep

116 L-17 signaling, acute inflammatory response, complement-mediated inflammation, and infection controll

117 HR1, which could result in an enhanced local complement-mediated inflammation, endothelial cell activ

118 plored as noninvasive in vivo diagnostics of complement-mediated inflammation, for spatiotemporal mon

119 ed to cells and is an excellent biomarker of complement-mediated inflammation.

120 n example of repetitive formation of ICs and complement-mediated inflammation.

121 to target neurotoxic aggregates and to avoid complement-mediated inflammatory responses, in order to

122 t contribute to the pathogenic mechanisms in complement-mediated, inflammatory diseases.

123 Complement mediated injury of the neuromuscular junction

124 ctivation leads to endothelial resistance to complement-mediated injury and protects from atherogenes

125 ystemic properdin as a key contributor to AP complement-mediated injury and support its therapeutic t

126 er endothelial cells and are associated with complement-mediated injury of the kidneys and vasculatur

127 HO-1)), which are particularly vulnerable to complement-mediated injury owing to their terminally dif

128 a compelling hypothesis for how FH prevents complement-mediated injury to host tissue while lacking

129 To establish the contribution of complement-mediated injury to the allograft microcircula

130 expression of TRPC6 protected podocytes from complement-mediated injury, whereas genetic or pharmacol

131 surface DAF and enhanced protection against complement-mediated injury.

132 d for IL-4-induced resistance of ECs against complement-mediated injury.

133 d this structure thus remained vulnerable to complement-mediated injury.

134 otor nerve terminal membrane might attenuate complement-mediated injury.

135 fected mice present a specific inhibition of complement-mediated internalization of IC caused by the

136 nal hemoglobinuria (PNH) is characterized by complement-mediated intravascular hemolysis because of t

137 nal hemoglobinuria (PNH) is characterized by complement-mediated intravascular hemolysis due to the l

138 59 on PNH red blood cells results in chronic complement-mediated intravascular hemolysis, a process c

139 introduction of a therapeutic that prevents complement-mediated intravascular hemolysis.

140 al manifestations of the disease result from complement-mediated intravascular hemolysis.

141 The in vivo effects of CSL040 on acute complement-mediated kidney damage were tested in an atte

142 ation between these genetic observations and complement-mediated kidney disease, these results provid

143 expression, binding of alemtuzumab and both complement-mediated killing and Ab-dependent cell-mediat

144 Both complement-mediated killing and cell-surface binding wer

145 otect pathogens from host defenses including complement-mediated killing and phagocytosis and therefo

146 and increased sensitivity of both strains to complement-mediated killing and the aminoglycoside antib

147 c acid had negative effects on resistance to complement-mediated killing and viability of biofilms in

148 hat exhibited an increased susceptibility to complement-mediated killing by neutrophils.

149 polyamines increase gonococcal resistance to complement-mediated killing by normal human serum.

150 possessed gonococcal Por1B were resistant to complement-mediated killing by normal human serum.

151 also resulted in decreased susceptibility to complement-mediated killing by normal human serum.

152 and several pathogens have adapted to avoid complement-mediated killing by sequestering fH to their

153 s increased resistance to antibody-dependent complement-mediated killing compared with enterocolitis-

154 The susceptibility to complement-mediated killing correlated with the amount o

155 equired for resistance to antibody-dependent complement-mediated killing in a murine model of infecti

156 and enhanced the resistance of the clade to complement-mediated killing in low levels of human compl

157 cate this protection involves a mechanism of complement-mediated killing in mammalian blood, a means

158 t component C3 deposition on the surface and complement-mediated killing of B. parapertussis.

159 terium from other antibodies that can induce complement-mediated killing of bacteria.

160 When this was tested, this serum facilitated complement-mediated killing of H. pylori and E. cloacae,

161 Antibodies that initiate complement-mediated killing of Neisseria meningitidis as

162 tibodies exhibited potent antibody-dependent complement-mediated killing of nonmucoid bacteria, they

163 Complement-mediated killing of Salmonella by healthy ser

164 fever, Rickettsia conorii, is susceptible to complement-mediated killing only in the presence of spec

165 Strains that resist antibody-induced, complement-mediated killing produce lipopolysaccharide c

166 t increased resistance to antibody-dependent complement-mediated killing secondary to genetic deletio

167 D59 expression, sensitizing neuroblastoma to complement-mediated killing triggered by anti-GD2 therap

168 meningitidis has several strategies to evade complement-mediated killing, and these contribute to its

169 of FH increases meningococcal resistance to complement-mediated killing.

170 ncluding protection of E. coli DH5alpha from complement-mediated killing.

171 o identify genes important for resistance to complement-mediated killing.

172 ion, antibody can protect the bacterium from complement-mediated killing.

173 n (methicillin) as well as susceptibility to complement-mediated killing.

174 tigen chain length and confers resistance to complement-mediated killing.

175 ibutes to the ability of gonococci to resist complement-mediated killing.

176 recipients given alemtuzumab without risk of complement-mediated killing.

177 nd membrane attack complex deposition and to complement-mediated killing.

178 Nm Opc binds to serum vitronectin to inhibit complement-mediated killing.

179 nesis of UTI and provides protection against complement-mediated killing.

180 nd the rck gene, features that resist direct complement-mediated killing.

181 l tract, perhaps via increased resistance to complement-mediated killing.

182 ection E. coli strain to become sensitive to complement-mediated killing.

183 everity, and did not mediate protection from complement-mediated killing.

184 ction E. coli strains were more sensitive to complement-mediated killing.

185 acid has been shown to protect bacteria from complement-mediated killing.

186 ance to temperature stress and resistance to complement-mediated killing.

187 spiratory tract, and confers protection from complement-mediated killing.

188 ammatory response of microglia is leading to complement-mediated loss of dopaminergic neurons.

189 mouse complement in vivo and to protect from complement-mediated lung injury but the mechanism of suc

190 re, was impaired in their ability to mediate complement mediated lysis and inhibited the complement-m

191 sis were reduced in their ability to mediate complement mediated lysis of target cells.

192 and, as a result, escape antibody-dependent complement-mediated lysis (ADCML).

193 ctivation (RCA) to resist antibody-dependent complement-mediated lysis (ADCML).

194 Binding of C1q to target-bound IgG initiates complement-mediated lysis (CML) of pathogens, as well as

195 infected patients became highly sensitive to complement-mediated lysis activated by either anti-HIV-1

196 c or bind host molecules function to prevent complement-mediated lysis and phagocytosis.

197 asured by enzyme-linked immunosorbent assay, complement-mediated lysis assay, and antibody-dependent

198 diverse microorganisms for phagocytosis and complement-mediated lysis by binding specific surface gl

199 enes demonstrated significant sensitivity to complement-mediated lysis compared with wild-type Schu S

200 We also found that mAb 2E8 caused complement-mediated lysis in DENV-infected cells.

201 Loss of CD55 and CD59 on erythrocytes causes complement-mediated lysis in paroxysmal nocturnal hemogl

202 la activate complement, but are resistant to complement-mediated lysis in part due to limited C3 depo

203 The strains with IS1301 in the IGR avoided complement-mediated lysis in the presence of bactericida

204 RA, and that these cells are susceptible to complement-mediated lysis in the presence of infliximab

205 a-CRIg inhibited MAC formation and prevented complement-mediated lysis in vitro.

206 educed immune complex precipitation, blocked complement-mediated lysis of Ab-sensitized RBC, and inhi

207 The CD20 mAb ofatumumab (OFA) induces complement-mediated lysis of B cells.

208 nti-HIV-1 Abs and complement did not mediate complement-mediated lysis of either erythrocytes or peri

209 ial virulence and is known to interfere with complement-mediated lysis of erythrocytes, but its exact

210 ally significant, reducing C9 deposition and complement-mediated lysis of flow-conditioned endothelia

211 Furthermore, mini-FH efficiently inhibited complement-mediated lysis of host-like cells caused by a

212 Their ability to mediate complement-mediated lysis of human monocytes and lymphoc

213 Phage therapy increases the efficacy of complement-mediated lysis of serum-resistant P. aerugino

214 eated promastigotes were more susceptible to complement-mediated lysis than untreated controls and re

215 including but not limited to (i) evasion of complement-mediated lysis, (ii) facilitation of macropha

216 hancing protection against C3 deposition and complement-mediated lysis, and this was reversed by DAF

217 ctica live vaccine strain) were resistant to complement-mediated lysis, but LVSG and LVSR (LVS strain

218 e examine the mechanisms of Ft resistance to complement-mediated lysis, C3 component deposition on th

219 e against invading microorganisms, including complement-mediated lysis, engulfment, formation of neut

220 rane protein that protects Y. pestis against complement-mediated lysis, on bubonic plague pathogenesi

221 h Ft.LVS, the mutant was highly sensitive to complement-mediated lysis, significantly attenuated in v

222 pendent cellular cytotoxicity, and by direct complement-mediated lysis.

223 antibody-dependent cellular cytotoxicity and complement-mediated lysis.

224 VCP was found to protect infected cells from complement-mediated lysis.

225 ors, regulation of apoptosis, and evasion of complement-mediated lysis.

226 rds P. falciparum merozoites protection from complement-mediated lysis.

227 or I contributes to S. aureus virulence by a complement-mediated mechanism.

228 In this study, we have defined complement-mediated mechanisms that enhance PGA formatio

229 important convergence point for antibody and complement mediated membrane injury in general, it forms

230 DM is an undeniably a complement-mediated microangiopathy with destruction of

231 ors, demonstrating a novel adaptive role for complement-mediated microglial clearance of apoptotic ph

232 There were 23 patients with complement-mediated MPGN and available eye examination r

233 classification system, and all patients with complement-mediated MPGN require screening eye examinati

234 ities are more prominent among patients with complement-mediated MPGN when compared with patients wit

235 These results demonstrate that complement-mediated muscle injury is central to the path

236 ain and discuss the autoimmune mechanisms of complement-mediated myopathies, myasthenia, peripheral n

237 ling in mice exposed to AGAbs indicates that complement-mediated necrosis occurs extensively in the p

238 They also define pathways of virus complement-mediated neutralization and suggest the desig

239 Viruses have evolved mechanisms to limit complement-mediated neutralization, some of which involv

240 we tested the in vitro sensitivity of NiV to complement-mediated neutralization.

241 ibution of these regulators in resistance to complement-mediated neutralization.

242 atant to protect the IMV, upon release, from complement-mediated neutralization.

243 into progeny virions as a mechanism to limit complement-mediated neutralization.

244 e gC and gE are postulated to interfere with complement-mediated neutralization.

245 The reduced capacity of complement-mediated opsonization and phagocytosis in the

246 a FH, which may contribute to GAS evasion of complement-mediated opsonization and phagocytosis.

247 Complement-mediated opsonization, phagocytosis, and immu

248 ly encapsulated based on their resistance to complement-mediated opsonophagocytic killing and their f

249 by approximately 50%, but did not influence complement-mediated opsonophagocytic killing by human ne

250 apsulated ATCC 15305 strain was resistant to complement-mediated opsonophagocytic killing by human ne

251 iofilm formation but was more susceptible to complement-mediated opsonophagocytic killing than the pa

252 in the IAV-infected LRT and protection from complement-mediated opsonophagocytosis due to capsular p

253 Evasion of complement-mediated opsonophagocytosis enables group A S

254 nt bound more C3 and was more susceptible to complement-mediated opsonophagocytosis than the parent s

255 either serotype C or D are more resistant to complement-mediated opsonophagocytosis than unencapsulat

256 w that zymosan-, immunoglobulin G (IgG)- and complement-mediated particle binding and phagocytosis we

257 However, its role in inflammation beyond complement-mediated pathogen clearance remains poorly de

258 Understanding the complexity of complement-mediated pathological mechanisms will aid in

259 ted the most attention, the diverse array of complement-mediated pathologies, with distinct underlyin

260 Similar responses may underlie other complement-mediated pathologies.

261 In GECs that overexpress iPLA(2)gamma, complement-mediated PGE(2) production was reduced by inh

262 ) integrin-mediated signaling cascade during complement-mediated phagocytosis and firm adhesion of po

263 elimination in the embryonic mouse retina by complement-mediated phagocytosis of non-apoptotic newbor

264 ffect alveolar macrophage viability, reduced complement-mediated phagocytosis of S. pneumoniae, while

265 ng ClfA(P336A Y338S) was more susceptible to complement-mediated phagocytosis than a ClfA-null mutant

266 Nonetheless, complement-mediated phagocytosis was enhanced within eac

267 bionts exhibited increased resistant against complement-mediated phagocytosis, and their intravenous

268 the capacity of capsular PS to interfere in complement-mediated phagocytosis, inhibit nitric oxide p

269 usly opsonized with antibody but never after complement-mediated phagocytosis.

270 ino mouse model may be a good model to study complement-mediated photoreceptor degeneration.

271 fficient mice, indicating a limited role for complement-mediated processes.

272 Complement-mediated production of PGE(2) was amplified i

273 These data demonstrate a critical role for complement-mediated regulation of the IL-23-T(H)17 axis

274 This is particularly so in the case of complement-mediated renal disease, where distinct sites

275 The complement-mediated renal diseases C3 glomerulopathy (C3

276 uraemic syndrome (aHUS) as well as the other complement-mediated renal diseases, including dense depo

277 nd in neurodegenerative disorders align with complement-mediated responses, and thus, thorough unders

278 RPC-reactive IgG levels induced more severe complement-mediated RPC damage than those with lower RPC

279 We measured human complement-mediated SBA responses in mice immunized with

280 s demonstrated that the classical pathway of complement mediated serum neutralization of influenza vi

281 the fH binding site, which result in greater complement-mediated serum bactericidal activity; these e

282 M. catarrhalis usually resists complement-mediated serum killing by recruiting to its s

283 field has uncovered novel pathways that link complement-mediated signalling with homeostatic and path

284 role of cytochrome P450 2B1 (CYP2B1) in this complement-mediated sublytic injury.

285 Complement-mediated synapse elimination has emerged as a

286 terferon response in neuroglia, resulting in complement-mediated synapse elimination in AD models.

287 ation of similar developmental mechanisms of complement-mediated synapse elimination potentially driv

288 ent inhibitors that protect synapses against complement-mediated synapse elimination remains unknown.

289 contain proteins that protect synapses from complement-mediated synapse elimination.

290 treatment of CNS diseases involving aberrant complement-mediated synapse loss.

291 Anti-CD45 antibody plus complement-mediated targeting of donor tissue is the mos

292 Eculizumab inhibited complement-mediated thrombotic microangiopathy and was a

293 enetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy.

294 rs in autoimmune patients may not only block complement-mediated tissue damage, but may also prevent

295 Rather, it might be more similar to complement-mediated TMA syndromes, which are well known

296 ical work-up of patients suspected of having complement-mediated TMA.

297 Although complement-mediated uptake requires macrophages to be PM

298 c enveloped viruses, including HIV-1, escape complement-mediated virolysis by incorporating host cell

299 of the viral envelope confers resistance to complement-mediated virolysis, which may explain why hum

300 ation of complement pathways, and subsequent complement-mediated virus neutralization.